Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome

NCT04729751 is registered in ClinicalTrials.gov with Mirum Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04729751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04729751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome
Lead sponsor
Mirum Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 9, 2021
Completion date
December 17, 2024
Enrollment
27 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

alagille syndrome, cholestatic liver disease, progressive familial intrahepatic cholestasis